Sierra Oncology Inc (NASDAQ:SRRA) – Investment analysts at SunTrust Banks upped their FY2017 EPS estimates for Sierra Oncology in a research note issued on Thursday. SunTrust Banks analyst Y. Suneja now forecasts that the biotechnology company will post earnings per share of ($0.84) for the year, up from their prior forecast of ($0.92). SunTrust Banks also issued estimates for Sierra Oncology’s Q4 2017 earnings at ($0.20) EPS, Q1 2018 earnings at ($0.21) EPS, Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.19) EPS, FY2018 earnings at ($0.86) EPS, FY2020 earnings at ($1.00) EPS and FY2021 earnings at ($1.00) EPS.
Sierra Oncology (NASDAQ:SRRA) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.03.
Several other equities research analysts have also weighed in on the company. Zacks Investment Research lowered Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. Jefferies Group LLC raised Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Monday, October 23rd. Finally, ValuEngine raised Sierra Oncology from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Sierra Oncology currently has a consensus rating of “Hold” and an average price target of $4.00.
Shares of Sierra Oncology (SRRA) opened at $1.94 on Monday. Sierra Oncology has a one year low of $1.10 and a one year high of $2.25.
An institutional investor recently bought a new position in Sierra Oncology stock. FMR LLC bought a new position in Sierra Oncology Inc (NASDAQ:SRRA) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 197,100 shares of the biotechnology company’s stock, valued at approximately $302,000. FMR LLC owned 0.38% of Sierra Oncology as of its most recent SEC filing. Institutional investors own 55.65% of the company’s stock.
Sierra Oncology Company Profile
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for Sierra Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.